4-哌啶基[4-(三氟甲基)苯基]甲酮 | 149452-44-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-哌啶基[4-(三氟甲基)苯基]甲酮
• 英文名称: 4-(4-trifluoromethylbenzoyl)piperidine
• 英文别名: piperidin-4-yl-[4-(trifluoromethyl)phenyl]methanone
• CAS: 149452-44-8
• 化学式: C₁₃H₁₄F₃NO
• 分子量: 257.255
• InChiKey: IZNSIDSQTFZSQP-UHFFFAOYSA-N

物化性质

• 沸点：
  334.0±42.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-isopropoxy-5-nitrobenzoic acid 、 4-哌啶基[4-(三氟甲基)苯基]甲酮 在 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以69%的产率得到(1-(2-isopropoxy-5-nitrobenzoyl)piperidin-4-yl)(4-(trifluoromethyl)phenyl)methanone
  参考文献：
  名称：

  Discovery of 4-benzoylpiperidine and 3-(piperidin-4-yl)benzo[d]isoxazole derivatives as potential and selective GlyT1 inhibitors

  摘要：

  两个系列的潜在和选择性GlyT1抑制剂通过生物同位素替代被发现。23q在慢性PCP处理的类精神分裂症行为模型上有效。

  DOI：

  10.1039/c5ra04714e
• 作为产物：
  描述：

  对溴三氟甲苯 在 盐酸 、 碘 、 magnesium 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 4.0h， 生成 4-哌啶基[4-(三氟甲基)苯基]甲酮
  参考文献：
  名称：

  Discovery of 4-benzoylpiperidine and 3-(piperidin-4-yl)benzo[d]isoxazole derivatives as potential and selective GlyT1 inhibitors

  摘要：

  两个系列的潜在和选择性GlyT1抑制剂通过生物同位素替代被发现。23q在慢性PCP处理的类精神分裂症行为模型上有效。

  DOI：

  10.1039/c5ra04714e

文献信息

• N-substituted alpha-arylazacycloalkylmethanamines and their use as
  申请人：A. H. Robins Company Incorporated

  公开号：US05198449A1

  公开（公告）日：1993-03-30

  Novel compounds of the formula below wherein W is azetidine, pyrrolidine or piperidine, Q is a straight chain hydrocarbon radical of 1-4 carbons and may contain a double bond, and ##STR1## Ar is phenyl, pyridinyl or pyrimidinyl, a process for their preparation, and novel intermediates are disclosed. The novel compounds and the pharmaceutical compositions of this invention are useful in the treatment of hypertension, arrhythmias and angina.

  以下是该公式的新化合物，其中W为氮杂环丙烷、吡咯烷或哌嗪，Q为含有1-4个碳原子的直链烃基，可能含有双键，Ar为苯基、吡啶基或嘧啶基。公开了它们的制备方法和新型中间体。该发明的新化合物和药物组合物在治疗高血压、心律失常和心绞痛方面具有用途。
• 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles
  申请人：Tsubouchi Hidetsugu

  公开号：US20060094767A1

  公开（公告）日：2006-05-04

  The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R 1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R 2 represents a group —OR 3 or the like, and R 3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R 1 and —(CH 2 ) n R 2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R 41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis , multi-drug-resistant Mycobacterium tuberculosis , and atypical acid-fast bacteria.

  本发明提供了一种2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物，其通式如下：其中，R1代表氢原子或C1-C6烷基，n代表0到6的整数，R2代表—OR3或类似的基团，R3代表氢原子、C1-C6烷基或类似的基团，或者R1和—(CH2)nR2可以通过相邻的碳原子通过氮原子结合在一起形成一个螺环，其通式为（H）：其中，R41为氢、C1-C6烷基或类似的基团。该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型酸性快速细菌具有优异的杀菌作用。
• Chemokine receptor binding compounds
  申请人：Zhou Yuanxi

  公开号：US20050277670A1

  公开（公告）日：2005-12-15

  The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

  本发明涉及化学因子受体结合化合物、制药组合物及其使用。更具体地，本发明涉及化学因子受体活性调节剂，优选为CCR5的调节剂。这些化合物表现出对人类免疫缺陷病毒（HIV）感染靶细胞的保护作用。
• N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines
  申请人：Ding Ping

  公开号：US20060166962A1

  公开（公告）日：2006-07-27

  It has now been found that certain novel N-(substituted aryl)-4-(disubstituted methyl)piperidine and pyridine derivatives have provided unexpected insecticidal activity. These compounds are represented by formula (I): wherein m, n, q, r, and s are independently selected from 0 or 1; and p is 0, 1, 2, or 3; A is CH or N; and B, D, E, R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are fully described herein. In addition, compositions comprising an insecticidally effective amount of at least one compound of formula I, and optionally, an effective amount of at least one of a second compound, with at least one insecticidally compatible carrier are also disclosed; along with methods of controlling insects comprising applying said compositions to a locus where insects are present or are expected to be present.

  现在已经发现某些新型N-（取代芳基）-4-（二取代甲基）哌啶和吡啶衍生物具有意外的杀虫活性。这些化合物由公式（I）表示：其中m、n、q、r和s独立地选自0或1；p为0、1、2或3；A为CH或N；B、D、E、R、R1、R2、R3、R4、R5、R6、R7和R8在此完全描述。此外，还披露了包含公式I中至少一种化合物的杀虫有效量的组合物，以及可选地，至少一种第二化合物的有效量，具有至少一种杀虫兼容载体；以及用于控制昆虫的方法，包括将所述组合物施用到昆虫存在或预计存在的地点。
• 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles
  申请人：Otsuka Pharmaceutical Co., Ltd.

  公开号：US07262212B2

  公开（公告）日：2007-08-28

  The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: wherein R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R2 represents a group —OR3 or the like, and R3 represents a hydrogen atom, C1-C6 alkyl group or the like, or R1 and —(CH2)nR2 may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H): wherein R41 is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria.

  本发明提供一种由以下通式表示的2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物：其中R1代表氢原子或C1-C6烷基，n代表0到6的整数，R2代表-OR3基团或类似基团，R3代表氢原子、C1-C6烷基或类似基团，或R1和-(CH2)nR2可以与相邻的碳原子通过氮原子结合在一起，形成由通式（H）表示的螺环：其中R41是氢、C1-C6烷基或类似基团。该化合物对结核分枝杆菌、多药耐药结核分枝杆菌和非典型酸性快速菌具有优异的杀菌作用。